Objectives Superb microvascular imaging (SMI) provides a more sensitive assessment of small vessels compared with power and colour Doppler ultrasonography (PDUS and CDUS). We aimed to investigate the ...

Inflammatory myopathies (IM) are a group of severe autoimmune diseases, sharing some similarities, whose cause is unknown and treatment is empirical. While C-protein-induced myositis (CIM), the most ...

Introduction The EULAR points to consider (PtC) for reducing non-adherence need implementation.Objectives To design, implement and evaluate a strategy based on the PtC to improve treatment adherence ...

Objectives Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) is linked to high mortality. Currently, effective screening tools are lacking. We assessed the role of symptoms and ...

Introduction The study aimed to identify and describe disease activity trajectories over 10 years in patients with recent-onset axial spondyloarthritis (axSpA) and determine their impact on long-term ...

It is known that 25%–30% of individuals with cutaneous psoriasis (PsC) will develop psoriatic arthritis (PsA). To date, the reasons for the development of PsA in individuals with PsC have not been ...

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to ...

Objectives To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA).

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases characterised by systemic involvement of small-to-medium vessels with necrotising inflammation that, by ...

Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were ...

Methods This prognostic study analysed patients with PM/DM-ILD admitted to Nanjing Drum Hospital from 2016 to 2021. The primary outcome was mortality within 1 year. We used a least absolute shrinkage ...

Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib ...